University of Texas Health Science Center San Antonio, San Antonio, Texas, USA.
Medical Center Ophthalmology Associates, San Antonio, Texas, USA.
Drugs Today (Barc). 2020 Nov;56(11):699-704. doi: 10.1358/dot.2020.56.11.3199812.
Given the success in stabilizing vision with current anti-vascular endothelial growth factor (VEGF) options, one main target for future anti-VEGF drug development includes creating medications with longer durations of action. Achieving this goal will decrease the number of overall injections and follow-up visits required to ensure better patient compliance. The smallest anti-VEGF created so far is brolucizumab (Beovu; Novartis). It is a 26-kDa IgG single-chain antibody fragment that delivers 11 times more anti-VEGF per injection than aflibercept. Brolucizumab was approved by the U.S. Food and Drug Administration (FDA) in late 2019 for the treatment of wet age-related macular degeneration, and has been also approved for the same indication in Japan and the European Union in 2020. In this article, we compare brolucizumab to current FDA-approved anti-VEGF treatments, address the studies associated with brolucizumab, discuss brolucizumab's side effects, and conclude with recommendations.
鉴于目前抗血管内皮生长因子（VEGF）药物在稳定视力方面的成功，未来抗 VEGF 药物开发的主要目标之一包括开发作用持续时间更长的药物。实现这一目标将减少所需的总注射次数和随访次数，以确保更好的患者依从性。迄今为止，最小的抗 VEGF 药物是 brolucizumab（Beovu；诺华公司）。它是一种 26kDa IgG 单链抗体片段，每次注射的抗 VEGF 含量是 aflibercept 的 11 倍。brolucizumab 于 2019 年底获得美国食品和药物管理局（FDA）批准，用于治疗湿性年龄相关性黄斑变性，2020 年在日本和欧盟也获得了相同适应证的批准。本文将 brolucizumab 与目前 FDA 批准的抗 VEGF 治疗药物进行比较，探讨与 brolucizumab 相关的研究，讨论 brolucizumab 的副作用，并提出建议。
